Loading...
Header Logo
Keywords
Last Name
Institution

ANNE TSAO

Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Forde PM, Scherpereel A, Tsao AS. Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol. 2019 Feb 14; 20(2):18. PMID: 30762130.
      View in: PubMed
    2. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565. PMID: 30322867.
      View in: PubMed
    3. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 Nov; 13(11):1655-1667. PMID: 30266660.
      View in: PubMed
    4. Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. J Thorac Oncol. 2018 Sep; 13(9):1269-1283. PMID: 29966799.
      View in: PubMed
    5. Tsao AS, Gladish GW, Gill RR. Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. J Thorac Oncol. 2018 Jul; 13(7):871-873. PMID: 29935841.
      View in: PubMed
    6. Nelson DB, Rice DC, Niu J, Atay SM, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao AS, Gomez DR, Giordano SH, Mehran RJ, Sepesi B. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018 05 01; 53(5):960-966. PMID: 29211849.
      View in: PubMed
    7. Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski MA, Shih JY, Tsao A, Lee P, Winfree KB, Sashegyi A, Cheng R, Varea R, Levy B, Garon E. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69. PMID: 29748017.
      View in: PubMed
    8. Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 Apr 20; 36(12):1260-1265. PMID: 29443651.
      View in: PubMed
    9. Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 2018 02 12; 33(2):244-258.e10. PMID: 29438696.
      View in: PubMed
    10. William WN, Tsao AS, Feng L, Ginsberg LE, Lee JJ, Kies MS, Glisson BS, Kim ES. Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. Oncologist. 2018 May; 23(5):526-e49. PMID: 29371473.
      View in: PubMed
    11. Milbury K, Tsao AS, Liao Z, Owns A, Engle R, Gonzalez EA, Bruera E, Cohen L. A research protocol for a pilot randomized controlled trial designed to examine the feasibility of a couple-based mind-body intervention for patients with metastatic lung cancer and their partners. Pilot Feasibility Stud. 2018; 4:37. PMID: 29416870.
      View in: PubMed
    12. Tsao AS, Lin H, Carter BW, Lee JJ, Rice D, Vaporcyan A, Swisher S, Mehran R, Heymach J, Nilsson M, Fan Y, Nunez M, Diao L, Wang J, Fujimoto J, Wistuba II, Hong WK. Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol. 2018 02; 13(2):246-257. PMID: 29313814.
      View in: PubMed
    13. Milbury K, Engle R, Tsao A, Liao Z, Owens A, Chaoul A, Bruera E, Cohen L. Pilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients With Metastatic Non-Small Cell Lung Cancer and Their Partners. J Pain Symptom Manage. 2018 03; 55(3):953-961. PMID: 29208478.
      View in: PubMed
    14. Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737. PMID: 29248169.
      View in: PubMed
    15. Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez D, Rice D, Mehran R, Scheinberg DA, Krug LM. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2017 Dec 15; 23(24):7483-7489. PMID: 28972039.
      View in: PubMed
    16. Nelson DB, Rice DC, Niu J, Atay S, Vaporciyan AA, Antonoff M, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao A, Gomez D, Giordano SH, Mehran R, Sepesi B. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3354-3362. PMID: 28817374.
      View in: PubMed
    17. Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Pérol M. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer. 2017 10; 112:181-187. PMID: 29191593.
      View in: PubMed
    18. Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273. PMID: 28729154.
      View in: PubMed
    19. Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017 08; 12(8):1299-1308. PMID: 28599887.
      View in: PubMed
    20. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
      View in: PubMed
    21. Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clin Lung Cancer. 2017 09; 18(5):589-593. PMID: 28690011.
      View in: PubMed
    22. Bekaii-Saab T, Goel S, Dickerson A, Von Roenn J, Thompson MA, Tsao AS. Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. J Oncol Pract. 2017 01; 13(1):e62-e67. PMID: 27875070.
      View in: PubMed
    23. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682. PMID: 27789196.
      View in: PubMed
    24. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647. PMID: 27480147.
      View in: PubMed
    25. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 08; 11(8):1246-1262. PMID: 27453164.
      View in: PubMed
    26. Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016 08 10; 34(23):2761-8. PMID: 27325859.
      View in: PubMed
    27. Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage. 2016 07; 52(1):8-16.e1. PMID: 27330023.
      View in: PubMed
    28. Tsao AS, Papadimitrakopoulou V, Lin H, Guo M, Lee JJ, Holsinger FC, Hong WK, Sturgis EM. Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infect Agent Cancer. 2016; 11:21. PMID: 27123042.
      View in: PubMed
    29. Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638. PMID: 27013409.
      View in: PubMed
    30. Lou Y, Pecot CV, Tran HT, DeVito VJ, Tang XM, Heymach JV, Luthra R, Wistuba II, Zuo Z, Tsao AS. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2016 Mar; 17(2):e5-11. PMID: 26700910.
      View in: PubMed
    31. Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56. PMID: 25800891.
      View in: PubMed
    32. Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015 Feb; 10(2):387-91. PMID: 25611229.
      View in: PubMed
    33. Tsao AS. Current readings: Window-of-opportunity trials for thoracic malignancies. Semin Thorac Cardiovasc Surg. 2014; 26(4):323-30. PMID: 25837547.
      View in: PubMed
    34. Gomez D, Tsao AS. Local and systemic therapies for malignant pleural mesothelioma. Curr Treat Options Oncol. 2014 Dec; 15(4):683-99. PMID: 25266654.
      View in: PubMed
    35. Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DR. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):149-56. PMID: 25442335.
      View in: PubMed
    36. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao A, Wistuba II. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol. 2014 Jul; 9(7):998-1007. PMID: 24926545.
      View in: PubMed
    37. Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba II. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92. PMID: 24669013.
      View in: PubMed
    38. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5. PMID: 24747001.
      View in: PubMed
    39. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014 Feb; 3(1):53-63. PMID: 25806281.
      View in: PubMed
    40. Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201. PMID: 24492162.
      View in: PubMed
    41. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906.
      View in: PubMed
    42. Gomez D, Tsao A, Rice D. Recurrence of malignant pleural mesothelioma at the resection borders--local or distant recurrence? J Thorac Oncol. 2013 Jul; 8(7):e65-6. PMID: 23774390.
      View in: PubMed
    43. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61. PMID: 23584298.
      View in: PubMed
    44. Tsao A, Hui EP, Juergens R, Marur S, Huat TE, Cher GB, Hong RL, Hong WK, Chan AT. Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Med. 2013 Jun; 2(3):351-9. PMID: 23930212.
      View in: PubMed
    45. Tsao AS, Papadimitrakopoulou V. The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer. 2013 Jul; 14(4):311-21. PMID: 23582282.
      View in: PubMed
    46. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42. PMID: 23442309.
      View in: PubMed
    47. Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb; 8(2):e19-20. PMID: 23328556.
      View in: PubMed
    48. Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45. PMID: 23247629.
      View in: PubMed
    49. Tsao AS. Mesothelioma. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S399-400. PMID: 23160333.
      View in: PubMed
    50. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52. PMID: 23059780.
      View in: PubMed
    51. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA, Lin SH. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20. PMID: 22819472.
      View in: PubMed
    52. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39. PMID: 22247021.
      View in: PubMed
    53. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11. PMID: 21892101.
      View in: PubMed
    54. Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DR. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011 Nov; 6(11):1938-45. PMID: 21964533.
      View in: PubMed
    55. Tsao AS, Heymach J. Mesothelioma and small cell lung cancer. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1825-6. PMID: 22005546.
      View in: PubMed
    56. Tsao AS, Papadimitrakopoulou V. Mitotic inhibitors. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1789-90. PMID: 22005531.
      View in: PubMed
    57. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319.
      View in: PubMed
    58. Tsao AS, Papadimitrakopoulou VA. The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park). 2011 Jun; 25(7):607, 614. PMID: 21888260.
      View in: PubMed
    59. Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-ß) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov; 12(6):369-74. PMID: 21729646.
      View in: PubMed
    60. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13. PMID: 21437893.
      View in: PubMed
    61. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol. 2011 Mar; 6(3):598-601. PMID: 21270668.
      View in: PubMed
    62. Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13. PMID: 21264827.
      View in: PubMed
    63. Garland L, Flores R, Tsao A. Individualizing mesothelioma treatment: small steps into a brighter future. Clin Lung Cancer. 2010 Nov 01; 11(6):371-3. PMID: 21062727.
      View in: PubMed
    64. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010 Jun 29; 2:15. PMID: 20587061.
      View in: PubMed
    65. Tsao AS, Roth JA, Herbst RS. Surgery: Future directions in multimodality therapy for NSCLC. Nat Rev Clin Oncol. 2010 Jan; 7(1):10-2. PMID: 20029443.
      View in: PubMed
    66. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010 Sep; 69(3):337-40. PMID: 20036440.
      View in: PubMed
    67. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41. PMID: 19892663.
      View in: PubMed
    68. Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HI. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009 Oct 24; 8:91. PMID: 19852844.
      View in: PubMed
    69. McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2009 Oct 01; 75(2):326-37. PMID: 19735859.
      View in: PubMed
    70. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol. 2009 Jun; 4(6):689-96. PMID: 19404214.
      View in: PubMed
    71. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90. PMID: 19255316.
      View in: PubMed
    72. Tsao AS, Mehran R, Roth JA. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer. 2009 Jan; 10(1):36-41. PMID: 19289370.
      View in: PubMed
    73. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008 Mar 20; 26(9):1472-8. PMID: 18349398.
      View in: PubMed
    74. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov; 84(5):1685-92; discussion 1692-3. PMID: 17954086.
      View in: PubMed
    75. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72. PMID: 17620427.
      View in: PubMed
    76. Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand MC, Kjaerheim K, Pass HI, Robinson B, Tsao A. Eighth international mesothelioma interest group. Oncogene. 2007 Oct 25; 26(49):6959-67. PMID: 17496929.
      View in: PubMed
    77. Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy. 2007; 9(2):144-57. PMID: 17453966.
      View in: PubMed
    78. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9. PMID: 16943532.
      View in: PubMed
    79. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006 Jun 01; 106(11):2428-36. PMID: 16634096.
      View in: PubMed
    80. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):231-9. PMID: 17409862.
      View in: PubMed
    81. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31. PMID: 16640804.
      View in: PubMed
    82. Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS, Walsh GL, Swisher SG, Hofstetter WL, Ordonez NG, Smythe WR. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005 Dec; 80(6):1988-92; discussion 1992-3. PMID: 16305830.
      View in: PubMed
    83. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55. PMID: 15753462.
      View in: PubMed
    84. Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2004 Jun 01; 100(11):2486-7; author reply 2487-8. PMID: 15160360.
      View in: PubMed
    85. Tsao AS, Shin DM, Palmer JL, Lee JS, Glisson BS. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer. 2004 May 15; 100(10):2240-5. PMID: 15139070.
      View in: PubMed
    86. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin. 2004 May-Jun; 54(3):150-80. PMID: 15195789.
      View in: PubMed
    87. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8. PMID: 15109537.
      View in: PubMed
    88. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003 Dec 01; 98(11):2483-7. PMID: 14635084.
      View in: PubMed
    89. Karp DD, Tsao AS, Kim ES. Nonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg. 2003 Oct; 15(4):405-20. PMID: 14710383.
      View in: PubMed
    90. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JM. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):660-4. PMID: 12869408.
      View in: PubMed
    91. Tsao AS, Kantarijian H, Talpaz M. STI-571 in chronic myelogenous leukaemia. Br J Haematol. 2002 Oct; 119(1):15-24. PMID: 12358949.
      View in: PubMed
    92. Tsao AS, Roth LM, Sandler A, Hurteau JA. Cervical primitive neuroectodermal tumor. Gynecol Oncol. 2001 Oct; 83(1):138-42. PMID: 11585426.
      View in: PubMed
    93. Curey TE, Goodey A, Tsao A, Lavigne J, Sohn Y, McDevitt JT, Anslyn EV, Neikirk D, Shear JB. Characterization of multicomponent monosaccharide solutions using an enzyme-based sensor array. Anal Biochem. 2001 Jun 15; 293(2):178-84. PMID: 11399030.
      View in: PubMed
    94. Goodey A, Lavigne JJ, Savoy SM, Rodriguez MD, Curey T, Tsao A, Simmons G, Wright J, Yoo SJ, Sohn Y, Anslyn EV, Shear JB, Neikirk DP, McDevitt JT. Development of multianalyte sensor arrays composed of chemically derivatized polymeric microspheres localized in micromachined cavities. J Am Chem Soc. 2001 Mar 21; 123(11):2559-70. PMID: 11456925.
      View in: PubMed
    95. Higdon K, Scott A, Tucci M, Benghuzzi H, Tsao A, Puckett A, Cason Z, Hughes J. The use of estrogen, DHEA, and diosgenin in a sustained delivery setting as a novel treatment approach for osteoporosis in the ovariectomized adult rat model. Biomed Sci Instrum. 2001; 37:281-6. PMID: 11347403.
      View in: PubMed
    96. Tramontana J, Benghuzzi H, Tucci M, Tsao A, Hughes J. Morphometric analysis of cortical bone upon the exposure to sustained delivery of anabolic promoting agents using adult male rats as a model. Biomed Sci Instrum. 2001; 37:293-8. PMID: 11347405.
      View in: PubMed
    97. Scott A, Higdon K, Tucci M, Benghuzzi H, Puckett A, Tsao A, Cason Z, Hughes J. The prevention of osteoporotic progression by means of steroid loaded TCPL drug delivery systems. Biomed Sci Instrum. 2001; 37:13-8. PMID: 11347375.
      View in: PubMed
    98. Blake K, Benghuzzi H, Cason Z, Tsao A, Puckett A. The role of the route of administration of poly-chlorinated biphenyls (PCBs) on the reproductive and vital organs of adult female rats. Biomed Sci Instrum. 2000; 36:159-64. PMID: 10834226.
      View in: PubMed
    99. Scott A, Higdon K, Benghuzzi H, Tucci M, Cason Z, England B, Tsao A, Hughes J. TCPL drug delivery system: the effects of synthetic DHEA and Diosgenin using an ovariectomized rat model. Biomed Sci Instrum. 2000; 36:171-6. PMID: 10834228.
      View in: PubMed
    100. Johnston W, Carr S, Benghuzzi H, Tucci M, Puckett A, Tsao A, Hughes J. Biochemical markers evaluation of RAW transformed cells during treatment with various biomaterials. Biomed Sci Instrum. 1999; 35:217-22. PMID: 11143350.
      View in: PubMed
    101. Carr S, Johnston W, Benghuzzi H, Tucci M, Puckett A, Tsao A, Hughes J. Morphological and biochemical modifications of human macrophages treated with various biomaterials. Biomed Sci Instrum. 1999; 35:211-6. PMID: 11143349.
      View in: PubMed
    102. McConachie A, Newman D, Tucci M, Puckett A, Tsao A, Hughes J, Benghuzzi H. The effect on bioadhesive polymers either freely in solution or covalently attached to a support on human macrophages. Biomed Sci Instrum. 1999; 35:45-50. PMID: 11143390.
      View in: PubMed
    103. Tucci M, Tsao A, Hughes J, Benghuzzi H. Non-specific immunohistochemical responses in surgical tissue collected from total joint arthroplasty. Biomed Sci Instrum. 1999; 35:223-8. PMID: 11143351.
      View in: PubMed
    104. Streckfus CF, Johnson RB, Nick T, Tsao A, Tucci M. Comparison of alveolar bone loss, alveolar bone density and second metacarpal bone density, salivary and gingival crevicular fluid interleukin-6 concentrations in healthy premenopausal and postmenopausal women on estrogen therapy. J Gerontol A Biol Sci Med Sci. 1997 Nov; 52(6):M343-51. PMID: 9402940.
      View in: PubMed
    105. Johnson R, Harrison D, Tucci M, Tsao A, Lemos M, Puckett A, Hughes JL, Benghuzzi H. Fibrous capsule formation in response to ultrahigh molecular weight polyethylene treated with peptides that influence adhesion. Biomed Sci Instrum. 1997; 34:47-52. PMID: 9603011.
      View in: PubMed
    106. Cavett W, Tucci M, Cason Z, Lemos L, England B, Tsao A, Benghuzzi H. Cellular responses to various levels of sustained delivery of testosterone in the ventral prostate. Biomed Sci Instrum. 1997; 33:155-60. PMID: 9731352.
      View in: PubMed
    107. Harrison D, Johnson R, Tucci M, Puckett A, Tsao A, Hughes J, Benghuzzi H. Interaction of cells with UHMWPE impregnated with the bioactive peptides RGD, RGE or Poly-L-lysine. Biomed Sci Instrum. 1997; 34:41-6. PMID: 9603010.
      View in: PubMed
    108. Tucci M, Tsao A, Hughes J. Analysis of capsular tissue from patients undergoing primary and revision total hip arthroplasty. Biomed Sci Instrum. 1996; 32:119-25. PMID: 8672658.
      View in: PubMed
    109. Callender M, Benghuzzi H, Tucci M, Mohamed A, Cason Z, Lemos L, Tsao A. Immunochemical and histopathological evaluation associated with sustained delivery of 5-alpha androstanedione using adult rats as a model. Biomed Sci Instrum. 1996; 32:55-62. PMID: 8672690.
      View in: PubMed
    110. Salloum G, Tucci M, Tsao A, Hughes J. Comparison of tissues adjacent to different mechanical stress areas from patients with clinically failed implants. Biomed Sci Instrum. 1995; 31:127-33. PMID: 7654949.
      View in: PubMed
    111. Improvement of clinical response and biomarkers by Camellia sinensis (green tea) extract in patients with high-risk oral premalignant lesions. Focus on Alternative and Complementary Therapies. 15:122-123.
    112. Immunotherapy in lung cancer. Translational Lung Cancer Research. 3:53-63.
    113. Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infectious Agents and Cancer. 11.
    114. Lung Cancer.
    115. Non-small cell lung cancer. 45-62.
    116. Novel therapies in metastatic head and neck squamous cell carcinoma. Community Oncology. 6:310-316.
    117. Cetuximab combined with chemotherapy in non-small cell lung cancer. Community Oncology. 7:17-22.
    118. Dexamethasone for Dyspnea in Cancer Patients. Journal of Pain and Symptom Management. 52:8-16.e1.
    119. The future of NSCLC. Oncology. 25.
    120. Reply to the letter to the editor entitled a practical guide to measure "all" malignant pleural mesothelioma tumors by modified RECIST criteria?. Journal of Thoracic Oncology. 6:2144-2145.
    121. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.
    122. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer.
    123. Consensus report of the 2015 Weinman international conference on mesothelioma. Journal of Thoracic Oncology. 11:1246-1262.
    124. Successful biochemoprevention in a patient with multiple aerodigestive malignancies. International Journal of Cancer Prevention. 2:297-300.
    125. Preface. Unknown Journal. xiii.
    126. Novel and Emerging Agents in NSCLC. 464-478.
    127. Scientific advances in lung cancer 2015. Journal of Thoracic Oncology. 11:613-638.
    128. Tyrosine-kinase inhibitors in oncology. 872-883.
    129. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 34:2761-2768.
    130. New Chemotherapeutic Agents in Lung Cancer. 315-333.
    131. The BATTLE-2 study. Journal of Clinical Oncology. 34:3638-3647.
    TSAO's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description